$1.72
+0.01(0.88%)
Mkt Cap $71M
$1.09
$3.40
52-Week Range
At a Glance
AI-generatedBeyondSpring Inc., a clinical-stage biopharmaceutical company, reported a net loss of $14.2 million for the fiscal year ended December 31, 2025.
8-K
BeyondSpring Inc. announced financial results for the full year ended December 31, 2025, reporting net loss from continuing operations of $8.7 million and cash, cash equivalents, and short-term investments of $12.6 million. The company highlighted Phase 3 survival benefits for Plinabulin in EGFR wild-type NSCLC from the DUBLIN-3 study and plans for the confirmatory DUBLIN-4 trial.$71M
Market Cap
—
Revenue
-$609.9K
Net Income
Employees40
Fundamentals
How The Business Makes Money
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001677940
ISINKYG108301006
CUSIPG10830100
Phone646 305 6387
Address28 Liberty Street, Florham Park, NY, 10005, US
SEC EDGAR